Introduction This manuscript aims to give an overview of current diagnostic, staging, and
prognostic markers for prostate cancer (PCa) and discuss emerging approaches. The …

Prostate‐specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer
but it possesses serious limitations. Therefore, there is an urgent need for more sensitive …

Objective: In recent years, several biomarkers alternative to standard prostate specific
antigen (PSA) for prostate cancer (PCa) diagnosis have become available. The aim of this …

Prostate cancer (PCa) is the second most frequently diagnosed cancer in men. Despite the
significant progress in cancer diagnosis and treatment over the last few years, the approach …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa
diagnosis. This article aims to provide concise information on the current findings that impact …

Current tendencies in the treatment course of prostate cancer patients increase the need for
reliable biomarkers that help in decision-making in a challenging clinical setting. Within the …

The introduction and widespread adoption of prostate-specific antigen (PSA) has
revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA …

Prostate cancer (PCa) belongs to most common cancers and it is the second leading cause
of cancer death in men. A genetic predisposition or acquired genetic and epigenetic …

In this review, a series of relatively well-documented ancillary biomarkers and emerging
molecular assays are evaluated for their relative ability to predict prognosis in prostate …